MIIST305
GI Mucosal Injury / Gastrointestinal Acute Radiation Syndrome (GI-ARS)
Pre-clinicalActive
Key Facts
Indication
GI Mucosal Injury / Gastrointestinal Acute Radiation Syndrome (GI-ARS)
Phase
Pre-clinical
Status
Active
Company
About Synedgen
Synedgen is a private, clinical-stage biotech founded in 2008, headquartered in Claremont, California. The company's core technology is the Multivalent Innate Immune Signaling Target (MIIST) platform, which generates glycopolymers designed to repair mucosal and dermal barriers. Its lead program, MIIST305, is a clinic-ready oral therapeutic for GI injury, with demonstrated preclinical efficacy in models like Acute Radiation Syndrome. The company is pre-revenue and is advancing its pipeline through internal development.
View full company profile